Exelixis, Inc. $EXEL Shares Sold by Peloton Wealth Strategists

Key Points

• Peloton Wealth Strategists reduced its stake in Exelixis, Inc. by 29.0%, now holding 31,830 shares valued at approximately $1.175 million.
• Varied institutional investments occurred in Q1, with Hemington Wealth Management increasing its holdings by 211.3% and Quarry LP growing its stake by a remarkable 4,900.0%.
• Analysts have set price targets for Exelixis, with Jefferies Financial Group rating it a "buy" at a target of $50.00, while the overall consensus is a "Moderate Buy" with an average target of $44.06.

Peloton Wealth Strategists cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 29.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,830 shares of the biotechnology company's stock after selling 13,000 shares during the quarter. Peloton Wealth Strategists' holdings in Exelixis were worth $1,175,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Hemington Wealth Management grew its holdings in shares of Exelixis by 211.3% during the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 522 shares during the last quarter. Bartlett & CO. Wealth Management LLC bought a new position in shares of Exelixis during the first quarter valued at approximately $37,000. Costello Asset Management INC bought a new position in shares of Exelixis during the first quarter valued at approximately $39,000. Harbour Investments Inc. grew its holdings in shares of Exelixis by 900.0% during the first quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 990 shares during the last quarter. Finally, Quarry LP grew its holdings in shares of Exelixis by 4,900.0% during the first quarter. Quarry LP now owns 2,000 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 1,960 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on EXEL. Jefferies Financial Group set a $50.00 target price on Exelixis and gave the company a "buy" rating in a report on Tuesday, June 24th. Citigroup upped their target price on Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a report on Thursday, May 15th. Benchmark reissued a "neutral" rating on shares of Exelixis in a report on Monday, June 23rd. Morgan Stanley decreased their price objective on Exelixis from $48.00 to $46.00 and set an "overweight" rating for the company in a report on Tuesday, July 29th. Finally, Stifel Nicolaus increased their price objective on Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a report on Tuesday, July 29th. Thirteen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $44.06.

Exelixis Price Performance

EXEL opened at $37.69 on Tuesday. The company has a market capitalization of $10.15 billion, a price-to-earnings ratio of 18.12, a price-to-earnings-growth ratio of 0.78 and a beta of 0.32. Exelixis, Inc. has a 1-year low of $25.12 and a 1-year high of $49.62. The business has a 50 day moving average price of $40.49 and a two-hundred day moving average price of $39.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. The firm had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm's revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Equities analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.